echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Target AVPR1A protein is expected to treat aggressive prostate cancer

    Target AVPR1A protein is expected to treat aggressive prostate cancer

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Reactivating AR signals promotecrPC production in low androgen environments after ADT treatmentThis AR activity occurs through a variety of mechanisms, including an increase in AR co-activation factors such as VAV3 and the expression of constituent AR variants such as clinically related AR-V7AR-V7 lacks ligand binding domains and is associated with poor prognosisrelcovaptan chemical structureresearchers at the University of Miami in the United States have previously found that VAV3 enhances AR-V7 activity, which promotes CRPC progressIn a new study, the researchers revealed that arginine vasopressin receptor 1a (arginine vasopressin 1a, AVPR1A) is the most commonly downgraded gene by analyzing the gene expression spectrum of CRPC cells that remove VAV3 or AR-V7, suggesting that this G-protein conjugate receptor may be critical to CRPCThe findings were recently published in the journal Science Translational Medicine under the title "Argine vasopressin either 1a is a therapeutic target for castration-adprostate cancer"AVPR1A is usually associated with maintaining blood pressure and body fluid balanceThe researchers found that it could help activate the signaling pathways involved in the development of anti-resistance in prostate canceranalysis of publicly available human prostate cancer data sets showed that AVPR1A had a higher number of copies and an increased number of mRNAs in advanced prostate cancerRemoving AVPR1A from CRPC cells can lead to reduced cell proliferation and cell cycle protein A decline, androgen-dependent prostate cancer, AR-negative prostate cancer, or non-tumor-dependent prostate epithelial cells have undetectable AVPR1A mRNA, and are therefore least affected by AVPR1A rejectionEctopic expression of AVPR1A in androgen-dependent prostate cancer cells can be given destoeroresistance both in vitro and in vivoin addition,, treating CRPC cells with AVPR1A ligand --- arginine pressurizin (AVP) --- activates ERK and CREB, a known promoter of prostate cancer progressionA clinically safe selective AVPR1A antagonist, relcovaptan, prevents the appearance of CRPC and reduces the insiticity of CRPC and bone metastasis in mouse models that simulate different stages of prostate cancerbased on these preclinical findings, AVPR1A antagonists are a promising CRPC treatment references: Ning Zhao et al Arginine vasopressin ei 1a is a target drug for castration-resistant prostate cancer Science Translational Medicine, 2019, doi:10.1126/scitranslmed.aaw4636.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.